Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

SoundThinking (SSTI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

SAN FRANCISCO--(BUSINESS WIRE)--Planet Labs PBC (NYSE: PL), a leading provider of daily data and insights about change on Earth, today announced it was selected as the primary subcontractor for the California Air Resource Board's (CARB) Satellite Data Purchase Program (SDPP). The $95M SDPP multi-year contract was awarded to Carbon Mapper with Planet as a subcontractor to provide the state of California with methane data built upon Tanager hyperspectral collections, and other Planet data product.

Micron's shares fell 8% on Friday, as its dour margin forecast took the shine off a robust quarterly revenue outlook driven by demand for its semiconductors used in artificial intelligence tasks.

NEW YORK, NY / ACCESS Newswire / March 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of OSI Systems, Inc. ("OSI" or the "Company") (NASDAQ:OSIS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

EDINBURGH, Scotland , March 21, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company"), (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that on March 20, 2025, it received notice that the Nasdaq Hearings Panel had determined to delist the Company's securities from The Nasdaq Stock Market LLC ("Nasdaq") due to the Company's failure to comply with Rule 5550(a)(2) of Nasdaq's Listing Rules. The Rule requires listed securities to maintain a minimum bid price of $1.00 per share.

NEW YORK, NY / ACCESS Newswire / March 21, 2025 / If you suffered a loss on your Constellation Brands, Inc. (NYSE:STZ) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/constellation-brands-inc-lawsuit-submission-form?prid=137810&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / March 21, 2025 / If you suffered a loss on your AppLovin Corporation (NASDAQ:APP) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/applovin-corporation-lawsuit-submission-form?prid=137809&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK CITY, NY / ACCESS Newswire / March 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of RLX Technology Inc. ("RLX" or the "Company") (NYSE:RLX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

NEW YORK, NY / ACCESS Newswire / March 21, 2025 / If you suffered a loss on your Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/maravai-lifesciences-holdings-inc-lawsuit-submission-form?prid=137807&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / March 21, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=137808&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK CITY, NY / ACCESS Newswire / March 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of XP Inc. ("XP" or the "Company") (NASDAQ:XP). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.